BTC Health (ASX:BTC) has reported consolidated revenue of $10.3 million for the year ended 30 June 2026, in line with the prior corresponding period, with the group returning to a positive EBITDA of $0.14 million, according to the Chair's address delivered at the company's annual general meeting on 19 November 2026.

Key Points

  • Consolidated revenue of $10.3 million for FY26, with gross margin improving to 42.5% and operating expenses decreasing 2% to $4.2 million
  • Adjusted EBITDA increased 49% to $0.27 million; group cash ended the year at $2.1 million, up 61%
  • Cardio revenue grew 31% to $5.9 million, representing 57% of group revenue, up from 44%
  • TGA approved a waiver allowing Bronchitol to be supplied in overseas-market packaging in Australia following manufacturer Arna Pharma entering voluntary administration
  • Dr Ian Kadish appointed to the Board on 1 October 2026, standing for election at the meeting

FY26 Financial Results

BTC Health recorded consolidated revenue of $10.3 million for the year ended 30 June 2026, with gross margin at 42.5% and operating expenses of $4.2 million. Group EBITDA was $0.14 million, while adjusted EBITDA reached $0.27 million. Unconsolidated statutory profit after tax was $34,728, compared with $3.98 million in the prior year, when a large fair value gain on investments was recorded following the Corcym transaction. Company net assets increased to $11.2 million. The first-half EBITDA loss of $0.10 million turned into a second-half EBITDA profit of $0.24 million as deferred orders were received and the lower cost base took effect.

Cardio Division Growth and New Distribution Agreements

Cardio revenue grew 31% to $5.9 million in FY26, now representing 57% of group revenue compared with 44% previously. Corcym heart valve sales reached $2.3 million in its first full year, cardiopulmonary bypass cannulas contributed $0.7 million in their first year, and the PEARS aortic root support implant grew 20% to $1.1 million. BTC Cardio moved from a small loss to a positive EBITDA of $0.17 million. The division also signed three new distribution agreements with SmartCanula, Andocor, and Jafron Biomedical. Infusion pump revenue fell 35% as the discontinued ambIT range sold through, neurospinal revenue declined 9%, and pharmaceutical revenue fell 13%.

Bronchitol Supply Disruption and New Product Agreements

In September 2026, BTC Health disclosed that Arna Pharma, the Sydney manufacturer of Bronchitol and Aridol, had entered voluntary administration. BTC Pharma is the Australian sponsor and exclusive distributor of both products. Aridol is currently out of stock. The TGA approved a waiver this week allowing Bronchitol packaged for overseas markets to be supplied in Australia, with supply expected to continue until the end of the 2027 calendar year. Additionally, BTC Pharma secured exclusive Australian and New Zealand rights to Sativex, a TGA-registered medicinal cannabis product, and BTC Cardio signed a new agreement with Exstent adding India to its PEARS territory, subject to Indian regulatory approval.